Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry

Hadi Yaziji, Clive R. Taylor, Neal S. Goldstein, David J. Dabbs, Elizabeth H. Hammond, Bryan Hewlett, Alton D. Floyd, Todd S. Barry, Alvn W. Martin, Sunil Badve, Frederick Baehner, Richard W. Cartun, Richard N. Eisen, Paul E. Swanson, Stephen M. Hewitt, Mogen Vyberg, David G. Hicks

Research output: Contribution to journalReview articlepeer-review

107 Scopus citations


Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines breast cancer prognosis after treatment with endocrine therapy. Although immunohistochemistry has been widely viewed as the gold standard methodology for ER testing in breast cancer, lack of standardized procedures, and lack of regulatory adherence to testing guidelines has resulted in high rates of "false-negative" results worldwide. Standardized testing is only possible after all aspects of ER testing-preanalytical, analytical, and postanalytical, have been closely controlled. A meeting of the "ad-hoc committee" of expert pathologists, technologists, and scientists, representing academic centers, reference laboratories, and various agencies, issued standardization testing recommendations, aimed at optimization of clinical ER testing environment, as a step toward improved standardized testing.

Original languageEnglish (US)
Pages (from-to)513-520
Number of pages8
JournalApplied Immunohistochemistry and Molecular Morphology
Issue number6
StatePublished - Dec 1 2008


  • Breast cancer
  • ER
  • Estrogen receptor
  • IHC
  • Immunohistochemistry
  • Standardization

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry'. Together they form a unique fingerprint.

Cite this